Financial News
Latest News about BLUE
Recent news which mentions BLUE
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
September 19, 2022
From Benzinga
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%
September 19, 2022
From Benzinga
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday
September 19, 2022
From Benzinga
FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know
September 17, 2022
Tickers
BLUE
From Benzinga
2 Risky Stocks That Are Running Low on Cash
September 13, 2022
From Motley Fool
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
September 10, 2022
Tickers
BLUE
From Motley Fool
Avoid Buying the Dip With These 2 Stocks During the Nasdaq Bear Market
September 06, 2022
From Motley Fool
From Benzinga
Should You Buy This Growth Stock Following a Major Approval?
August 23, 2022
Tickers
BLUE
From Motley Fool
Why Bluebird Bio's Stock Dived by Over 11% This Week
August 19, 2022
From Motley Fool
From Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
August 18, 2022
From Benzinga
Dear AAPL Stock Fans, Mark Your Calendars for Sept. 7
August 18, 2022
From InvestorPlace
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy
August 18, 2022
From InvestorPlace
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
August 18, 2022
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 18, 2022
From Benzinga
From InvestorPlace
From Benzinga
This contrarian investor gave a timely warning for the last big tech top. He now sees the biggest drop of this bear market dead ahead.
August 18, 2022
From MarketWatch
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
August 18, 2022
From Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 17, 2022
From Benzinga
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
August 17, 2022
Tickers
BLUE
From Benzinga
Bluebird's Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
August 17, 2022
Tickers
BLUE
From Benzinga
From Motley Fool
From Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
From Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.